Biologics for asthma最新文献

S87 Severe asthma outcomes when switching from mepolizumab to benralizumab in non-responders with persistent sputum eosinophilia 持续痰嗜酸性粒细胞增多症无应答者从美波珠单抗切换到贝纳利珠单抗时的严重哮喘结局

Biologics for asthma Pub Date : 2021-11-01 DOI: 10.1136/thorax-2021-btsabstracts.93

G. Tavernier, M. Philbin, L. Holmes, L. Elsey, D. Allen, S. Fowler

引用次数: 0

S84 Long-term efficacy of dupilumab: 3-year data of QUEST patients with moderate-to-severe asthma enrolled in LIBERTY ASTHMA TRAVERSE dupilumab的长期疗效:LIBERTY asthma TRAVERSE纳入的中重度哮喘QUEST患者的3年数据

Biologics for asthma Pub Date : 2021-11-01 DOI: 10.1136/thorax-2021-btsabstracts.90

I. Pavord, A. Papi, A. Bourdin, H. Watz, C. Domingo, M. Wechsler, X. Mao, B. Ortiz, M. Djandji, L. Mannent, E. Laws, N. Amin, D. Lederer, M. Hardin

引用次数: 0

S83 The impact of an online patient-facing tool on severe asthma referrals 在线面向患者的工具对严重哮喘转诊的影响

Biologics for asthma Pub Date : 2021-11-01 DOI: 10.1136/thorax-2021-btsabstracts.89

C. Renwick, C. Cheung, A. Fallas, J. Kirby, S. Walker

引用次数: 0

S86 Long-term assessment of exacerbations and lung function in the LIBERTY ASTHMA TRAVERSE study, stratified by lung function improvements at the end of the phase 3 LIBERTY ASTHMA QUEST parent study S86 LIBERTY ASTHMA TRAVERSE研究中急性加重和肺功能的长期评估，根据3期LIBERTY ASTHMA QUEST亲本研究结束时肺功能改善进行分层

Biologics for asthma Pub Date : 2021-11-01 DOI: 10.1136/thorax-2021-btsabstracts.92

A. Bourdin, N. Hanania, D. Dorscheid, X. Muñoz, Y. Tohda, N. Daizadeh, J. Jacob-Nara, B. Ortiz, M. Djandji, Y. Deniz, P. Rowe

{"title":"S86 Long-term assessment of exacerbations and lung function in the LIBERTY ASTHMA TRAVERSE study, stratified by lung function improvements at the end of the phase 3 LIBERTY ASTHMA QUEST parent study","authors":"A. Bourdin, N. Hanania, D. Dorscheid, X. Muñoz, Y. Tohda, N. Daizadeh, J. Jacob-Nara, B. Ortiz, M. Djandji, Y. Deniz, P. Rowe","doi":"10.1136/thorax-2021-btsabstracts.92","DOIUrl":"https://doi.org/10.1136/thorax-2021-btsabstracts.92","url":null,"abstract":"S86 Table 1 Efficacy endpoints during QUEST and TRAVERSE in type 2 QUEST patients stratified by level of pre-bronchodilator FEV1 improvement at Week 52 of QUEST <100mL improvement $100mL improvement $200mL improvement Combined PBO Combined DPL Combined PBO Combined DPL Combined PBO Combined DPL Number of severe asthma exacerbations experienced in the year prior to QUEST (exacerbation history) N 32 70 199 462 158 398 Mean (SD) 2.19 (1.97) 1.96 (1.71) 2.27 (1.97) 2.09 (2.00) 2.20 (1.85) 2.12 (2.10) Adjusted annualized event rate of severe exacerbation during 52-week treatment period of QUEST Patients with $1 severe exacerbation events, n (%) 12(37.5) 18 (25.7) 72(36.2) 109 (23.6) 53 (33.5) 94(23.6) Estimate 0.690 0.481 0.679 0.331 0.704 0.331 Relative risk (95% CI) vs matching placebo 0.697 (0.291, 1.667) P = 0.4134 0.487 (0.355, 0.669) P < 0.0001 0.471 (0.330, 0.673) P < 0.0001 Unadjusted annualized event rate of severe exacerbation by year during treatment period of TRAVERSE PBO/DPL DPL/DPL PBO/DPL DPL/DPL PBO/DPL DPL/DPL Patients with $1 severe exacerbation events, Weeks 0–48, n/N (%) 8/32 (25.0)","PeriodicalId":334138,"journal":{"name":"Biologics for asthma","volume":"72 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128951229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

S88 Use of a connected inhaler system in the pre-biologic assessment of patients with severe asthma S88使用连接吸入器系统对严重哮喘患者进行生物前评估

Biologics for asthma Pub Date : 2021-11-01 DOI: 10.1136/thorax-2021-btsabstracts.94

J. Holmes, P. Dennison, D. Jackson, G. d'Ancona, A. Mansur, A. Menzies-Gow, P. Patel, P. Pfeffer, C. Chen, D. Shaw, Propeller Health, L. Heaney

引用次数: 0

S85 Clinical characteristics associated with mucus plugging in severe eosinophilic asthma and the effectiveness of benralizumab treatment S85:严重嗜酸性粒细胞性哮喘患者黏液堵塞的临床特征及苯那利珠单抗治疗的有效性

Biologics for asthma Pub Date : 2021-11-01 DOI: 10.1136/thorax-2021-btsabstracts.91

A. Hearn, M. Mak, I. Budaj, N. Qurashi, O. Snell, J. Kavanagh, M. Fernandes, L. Green, C. Roxas, L. Thomson, G. d'Ancona, J. Dhariwal, A. Nanzer, D. Jackson

{"title":"S85 Clinical characteristics associated with mucus plugging in severe eosinophilic asthma and the effectiveness of benralizumab treatment","authors":"A. Hearn, M. Mak, I. Budaj, N. Qurashi, O. Snell, J. Kavanagh, M. Fernandes, L. Green, C. Roxas, L. Thomson, G. d'Ancona, J. Dhariwal, A. Nanzer, D. Jackson","doi":"10.1136/thorax-2021-btsabstracts.91","DOIUrl":"https://doi.org/10.1136/thorax-2021-btsabstracts.91","url":null,"abstract":"severe asthma exacerbations (AER) during QUEST (Weeks 0– 52) and TRAVERSE (Weeks 0–48 and Weeks 48–96) and the mean change from QUEST baseline in pre-bronchodilator FEV1 in QUEST over the QUEST and TRAVERSE studies. Results The unadjusted AER in dupilumab-treated patients was low during QUEST, with progressive reductions observed during the treatment period of 96 weeks in TRAVERSE and a majority of patients experiencing no exacerbations (figure 1A). In the placebo/dupilumab group of patients, the unadjusted AER decreased significantly during TRAVERSE compared with QUEST and was similar to the AER in dupilumab/dupilumab patients. Clinically meaningful improvements in pre-bronchodilator FEV1 were observed at Week 52 of QUEST in dupilumab/dupilumab patients, which were sustained with no apparent loss of treatment effect at Weeks 48 and 96 of TRAVERSE (figure 1B). Large improvements in pre-bronchodilator FEV1 were observed in placebo/dupilumab patients upon initiation of dupilumab, which were sustained throughout the TRAVERSE treatment period. Conclusions Dupilumab demonstrated sustained efficacy in reducing severe asthma exacerbations and improving lung function in patients with moderate-to-severe asthma who completed 96 weeks of treatment.","PeriodicalId":334138,"journal":{"name":"Biologics for asthma","volume":"12 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126368065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0